Compare · ORCL vs SNCE
ORCL vs SNCE
Side-by-side comparison of Oracle Corporation (ORCL) and Science 37 Holdings Inc. (SNCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORCL and SNCE operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- ORCL carries a market cap of $374.13B.
- ORCL has hit the wire 55 times in the past 4 weeks while SNCE has been quiet.
- ORCL has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- Oracle Corporation
- Science 37 Holdings Inc.
- Price
- -
- -
- Market cap
- $374.13B
- -
- 1M return
- -14.47%
- -
- 1Y return
- -50.54%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NYSE
- NASDAQ
- IPO
- 1986
- 2020
- News (4w)
- 55
- 0
- Recent ratings
- 25
- 5
Oracle Corporation
Oracle Corporation provides products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Fusion cloud advertising and customer experience, and NetSuite applications suite. The company also offers cloud-based industry solutions for various industries; Oracle application licenses; and Oracle license support services. In addition, it provides cloud and license business' infrastructure technologies, such as the Oracle Database, an enterprise database; Java, a software development language; and middleware, including development tools and others. The company's cloud and license business' infrastructure technologies also comprise cloud-based compute, storage, and networking capabilities through its Oracle cloud infrastructure as a service offerings. Further, it offers infrastructure offerings comprising Oracle autonomous data warehouse cloud service, Oracle autonomous transaction processing cloud service, Internet-of-Things, digital assistant, and blockchain. Additionally, the company provides hardware products and other hardware-related software offerings, including Oracle engineered systems, enterprise servers, storage solutions, industry-specific hardware, virtualization software, operating systems, management software, and related hardware services; and consulting services. The company markets and sells its cloud, license, hardware, support, and services offerings directly to businesses in various industries, government agencies, and educational institutions, as well as through indirect channels. Oracle Corporation was founded in 1977 and is headquartered in Austin, Texas.
Latest ORCL
- Oracle Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Chubu Electric Power Grid Launches 10 Millionth Smart Meter with Oracle
- SEC Form 424B5 filed by Oracle Corporation
- Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes
- SEC Form FWP filed by Oracle Corporation
- SEC Form 424B5 filed by Oracle Corporation
- SEC Form S-3ASR filed by Oracle Corporation
- Oracle upgraded by Stephens with a new price target
- SEC Form 8-K filed by Oracle Corporation
- Oracle Investor Day 2026: Accelerating Value Creation
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance